Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
2,468.7
-2.9 (-0.12%)

 

  • STI Straits Times Index
    2,468.7
    -2.9 (-0.12%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,510.1
    6.2 (0.41%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    23,477.7
    202.2 (0.87%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,225.4
    1.1 (0.03%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    23,185.1
    -354.0 (-1.50%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    4,860.1
    -19.0 (-0.39%)
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 776.6M
  • Value: 804.1M
  • Rise: 110
  • Fall: 136
  • Unch: 533

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Sembcorp Marine0.148+0.004
HPH Trust USD0.161+0.015
Jiutian Chemical0.048-0.002
Singtel2.110+0.010
Beverly JCG0.001-0.001
CapitaMall Trust1.940-0.050
Keppel Corp4.410+0.110
Rex Intl0.140-0.002
ThaiBev0.600+0.005
Vividthree0.070-0.005

World Indices

World Indices
Name Last Change
Nasdaq 10,672.3 +39.3
HSI 23,235.4 -75.7
HSCEI 9,302.6 -68.6
Jakarta 4,945.8 +103.0
Nikkei 225 23,204.6 +116.8
SSE Comp 3,219.4 -3.8
Shanghai A 3,374.1 -4.0
Shanghai B 247.4 +0.8
KOSPI 2,278.8 +6.1

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

Hyphens Pharma HYPHENS PHARMA INTL LIMITED
Quotes 10 Minutes Delayed. Updated at 30 Sep 2020 15:09
Last (SGD): 0.400 Change: -0.005 High: 0.415 Remarks: -
Change (%): -1.23 Low: 0.385
Open 0.400 Yesterday's Close 0.405
Buy Price 0.395 Sell Price 0.400
Buy Volume ('000) 65.3 Sell Volume ('000) 40.0
Cumulative Volume ('000) 1,899.4 Cumulative Value 755,450
Click to show Stock Prices chart

Key Statistics

EPS (SGD) a 0.02174 Trailing EPS (SGD) e 0.02579 NAV (SGD) b 0.1507
PE a 18.399 Trailing PE f 15.510 Price / NAV b 2.6543
Dividend (SGD) d 0.010000 Cash In Hand (SGD) g 0.0868 Issued & Paid-up Shares c 300,430,000
Dividend Yield (%) d 2.500 Price / Cash In Hand g 4.608 Treasury Shares h -
Beta - 75 Daysi 0.015 R-Squared - 75 Days(%)i 0.06 Market Cap (M) 120.172
Beta - 500 Daysi 0.343 R-Squared - 500 Days (%)i 0.79 Enterprise Value (M) 97.725
Piotroski F Score 6 Exchange Code 1J5 Par Value ( SGD ) n.a.
52 Weeks Volatility (%) 60.1559 6-Month VWAP 0.450 Free Float (%) 20.4
Under CPF Investment Scheme (CPFIS) No
Sector & Industry Wholesale and Retail Trade - Pharmaceuticals: Major
Category Classification Medical & Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 18 Aug 2020.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand.
  9. Beta and R-Squared are calculated in relation to the market index (STI or KLCI) using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference Hyphens Pharma SGX 120.172 18.399 15.510 2.6543 2.500
Industry Medical & Biotechnology SGX 920.274 21.721 20.996 1.3096 2.087
Pharmaceuticals: Major SGX 95.249 2431.015 115.115 4.2677 1.051
Local Peer IX Biopharma SGX 159.479 - - 7.8231 -
Local Peer Pharmesis Intl SGX 6.095 - - 0.5290 -
Global Peer JOHNSON & JOHNSON NYSE 387,182.509 25.609 25.498 6.1479 2.550
Global Peer NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) NYSE 214,732.902 30.466 29.749 3.9904 2.117
Global Peer MERCK & CO INC NYSE 207,144.756 21.045 19.768 7.4938 2.770
Global Peer PFIZER INC NYSE 200,992.350 12.352 14.184 3.1241 4.020
Global Peer ABBVIE INC NYSE 153,346.079 19.554 22.218 10.4261 4.234
Global Peer ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS NASDAQ 144,640.604 107.898 190.856 11.8198 2.486
Global Peer ELI LILLY AND COMPANY NYSE 139,893.302 30.163 24.900 34.1793 1.766
Global Peer BRISTOL-MYERS SQUIBB CO NYSE 135,010.407 39.259 - 2.7500 2.772
Global Peer NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS B DKK1 NYSE 127,277.963 21.797 20.751 14.0643 1.619
Global Peer SANOFI SPON ADR ECH REP 0.5 ORD SHS NASDAQ 127,152.435 39.080 10.352 1.7884 2.314
Other Global Peers GLAXOSMITHKLINE ADR EACH CNV INTO 2 ORD GBP0.25 (NYSE), TAKEDA PHARMACEUTICAL CO LTD SPON ADS EACH REP 0.5 ORD SHS (NYSE), WUXI APPTEC (HKEx), HANSOH PHARMA (HKEx), ROYALTY PHARMA PLC (NASDAQ), INNOVENT BIO (HKEx), CUREVAC NV (NASDAQ), REPLIGEN CORP (NASDAQ), CANSINOBIO-B (HKEx), SINOPHARM (HKEx), JUNSHI BIO (HKEx), SH PHARMA (HKEx), HUTCHISON CHINA MEDITECH SPON ADS EACH REPR 5 ORD SHS (NASDAQ), GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 (NASDAQ), LEGEND BIOTECH CORP SPON ADS EACH REP 2 ORD SHS (NASDAQ), BAIYUNSHAN PH (HKEx), ALLAKOS INC (NASDAQ), BIOHAVEN PHARMACEUTICAL HLDG CO LTD (NYSE), TURNING POINT THERAPEUTICS INC (NASDAQ), HYGEIA HEALTH (HKEx), PRINCIPIA BIOPHARMA INC (NASDAQ), HENLIUS-B (HKEx), CHINAGRANDPHARM (HKEx), CHINARES PHARMA (HKEx), REATA PHARMACEUTICALS INC (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), AKESO-B (HKEx), CMS (HKEx), I MAB SPON ADS EACH REP 2.3 ORD SHS (NASDAQ), HEPALINK (HKEx), ADC THERAPEUTICS SA (NYSE), OPKO HEALTH INC (NASDAQ), IGM BIOSCIENCES INC (NASDAQ), APELLIS PHARMACEUTICALS INC (NASDAQ), TRAD CHI MED (HKEx), KARUNA THERAPEUTICS INC (NASDAQ), ZYMEWORKS INC (NYSE), FORMA THERAPEUTICS HLDGS INC (NASDAQ), SPRINGWORKS THERAPEUTICS INC (NASDAQ), HARMONY BIOSCIENCES HLDGS INC (NASDAQ), UNITED LAB (HKEx), AKCEA THERAPEUTICS INC (NASDAQ), OCUMENSION-B (HKEx), SSY GROUP (HKEx), INNOCARE-B (HKEx), Y-MABS THERAPEUTICS INC (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), GENERATION BIO CO (NASDAQ), CSTONE PHARMA-B (HKEx), NURIX THERAPEUTICS INC (NASDAQ), ARCUTIS BIOTHERAPEUTICS INC (NASDAQ), REPARE THERAPEUTICS INC (NASDAQ), AMNEAL PHARMACEUTICALS INC (NYSE), Kimia Farma Tbk. (IDX), CKLIFE SCIENCES (HKEx), ATHENEX INC (NASDAQ), AKERO THERAPEUTICS INC (NASDAQ), ANNEXON INC (NASDAQ), QUANTERIX CORPORATION (NASDAQ), KINIKSA PHARMACEUTICALS LTD (NASDAQ), ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ), PHATHOM PHARMACEUTICALS INC (NASDAQ), GOSSAMER BIO INC (NASDAQ), CONSTELLATION PHARMACEUTICALS INC (NASDAQ), PETIQ INC (NASDAQ), TONGRENTANGCM (HKEx), KRYSTAL BIOTECH INC (NASDAQ), Soho Global Health Tbk. (IDX), KEROS THERAPEUTICS INC (NASDAQ), PROVENTION BIO INC (NASDAQ), PHIBRO ANIMAL HEALTH CORP (NASDAQ), ORIC PHARMACEUTICALS INC (NASDAQ), IMMUNOTECH-B (HKEx), TCR2 THERAPEUTICS INC (NASDAQ), HUA MEDICINE-B (HKEx), RELMADA THERAPEUTICS INC (NASDAQ), CALLIDITAS THERAPEUTICS AB SPON ADS EACH REP 2 ORD SHS (NASDAQ), ODONATE THERAPEUTICS INC (NASDAQ), INOZYME PHARMA INC (NASDAQ), SIGA TECHNOLOGIES INC (NASDAQ), IGBB (Bursa), OYSTER POINT PHARMA INC (NASDAQ), CRINETICS PHARMACEUTICALS INC (NASDAQ), 89BIO INC (NASDAQ), MIRUM PHARMACEUTICALS INC (NASDAQ), OCULAR THERAPEUTIX INC (NASDAQ), FUSION PHARMACEUTICALS INC (NASDAQ), APREA THERAPEUTICS INC (NASDAQ), SHINEWAY PHARM (HKEx), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), APPLIED THERAPEUTICS INC (NASDAQ), G1 THERAPEUTICS IN (NASDAQ), BIONDVAX PHARMACEUTICALS SPON ADS REP 40 ORD SHS (NASDAQ), KALA PHARMACEUTICALS INC (NASDAQ), TRICIDA INC (NASDAQ), STARPHARMA HOLDINGS LIMITED (ASX), AMRYT PHARMA PLC (NEW) SPON ADS EACH REP 5 ORD SHS (NASDAQ), BEYONDSPRING INC (NASDAQ), ORCHARD THERAPEUTICS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), BIOSPECIFICS TECHNOLOGIES CORP (NASDAQ), IMMUNIC INC (NASDAQ), TFF PHARMACEUTICALS INC (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), OVID THERAPEUTICS INC (NASDAQ), IMARA INC (NASDAQ), FUSEN PHARM (HKEx), SUTRO BIOPHARMA INC (NASDAQ), KALEIDO BIOSCIENCES INC (NASDAQ), DURECT CORP (NASDAQ), AFT PHARMACEUTICALS LTD (ASX), AC IMMUNE SA (NASDAQ), OSMOTICA PHARMACEUTICALS PLC (NASDAQ), IDEAYA BIOSCIENCES INC (NASDAQ), PYC THERAPEUTICS LIMITED (ASX), AMAG PHARMACEUTICS INC (NASDAQ), TOT BIOPHARM-B (HKEx), BSTEAD (Bursa), UROVANT SCIENCES LTD (NASDAQ), VYNE THERAPEUTICS INC (NASDAQ), PHARMA (Bursa), XERIS PHARMACEUTICALS INC (NASDAQ), SPERO THERAPEUTICS INC (NASDAQ), HOOKIPA PHARMA INC (NASDAQ), LANNETT CO INC (NYSE), CYCLERION THERAPEUTICS INC (NASDAQ), KALVISTA PHARMACEUTICALS INC (NASDAQ), LOGICBIO THERAPEUTICS INC (NASDAQ), EVELO BIOSCIENCES INC (NASDAQ), GALERA THERAPEUTICS INC (NASDAQ), FULCRUM THERAPEUTICS INC (NASDAQ), VERRICA PHARMACEUTICALS INC (NASDAQ), GAMIDA CELL LTD (NASDAQ), POLYPID LTD (NASDAQ), SCPHARMACEUTICALS INC (NASDAQ), ESSA PHARMA INC (NASDAQ), CHECKPOINT THERAPEUTICS INC (NASDAQ), MILESTONE PHARMACEUTICALS INC (NASDAQ), LIQUIDIA TECHNOLOGIES INC (NASDAQ), DAWNRAYS PHARMA (HKEx), AVENUE THERAPEUTICS INC (NASDAQ), VERU INC (NASDAQ), ZHONGZHIPHARM (HKEx), MUSTANG BIO INC (NASDAQ), CH BIOTECH SER (HKEx), PROTARA THERAPEUTICS INC (NASDAQ), NEUBASE THERAPEUTICS INC (NASDAQ), THERATECHNOLOGIES INC (NASDAQ), SOL GEL TECHNOLOGIES LTD (NASDAQ), ETON PHARMACEUTICALS INC (NASDAQ), AYALA PHARMACEUTICALS INC (NASDAQ), LYRA THERAPEUTICS INC (NASDAQ), AQUESTIVE THERAPEUTICS INC (NASDAQ), BIOMX INC (NYSE American), HARROW HEALTH INC (NASDAQ), APTORUM GROUP LIMITED (NASDAQ), OBSEVA SA (NASDAQ), EVOLUS INC (NASDAQ), LANTERN PHARMA INC (NASDAQ), GENPREX INC (NASDAQ), TYME TECHNOLOGIES INC (NASDAQ), RECCE PHARMACEUTICALS LTD (ASX), CORVUS PHARMACEUTICALS INC (NASDAQ), KOTRA (Bursa), MEDIWOUND LTD (NASDAQ), PHASEBIO PHARMACEUTICALS INC (NASDAQ), GRITSTONE ONCOLOGY INC (NASDAQ), Merck Tbk. (IDX), NEW RAY MEDIC (HKEx), IP (SET), Phapros Tbk. (IDX), ONCOSIL MEDICAL LIMITED (ASX), EDESA BIOTECH INC (NASDAQ), EYENOVIA INC (NASDAQ), NEP INTERLONG (HKEx), KITOV PHARMA LTD SPON ADS EACH REP 10 ORD SHS (R/S) (NASDAQ), PAK FAH YEOW (HKEx), TREVI THERAPEUTICS INC (NASDAQ), ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ), RACE ONCOLOGY LTD (ASX), ASSERTIO HOLDINGS INC (NASDAQ), CLEARSIDE BIOMEDICAL INC (NASDAQ), NOVA (Bursa), NOVAN INC (NASDAQ), EYEPOINT PHARMACEUTICALS INC (NASDAQ), SATSUMA PHARMACEUTICALS INC (NASDAQ), PALLA PHARMA LTD (ASX), ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 6 ORD SHS (NASDAQ), ARIDIS PHARMACEUTICAL INC (NASDAQ), CHARMACY PHAR (HKEx), AERPIO PHARMACEUTICALS INC (NASDAQ), NC HEALTHCARE (HKEx), NOXOPHARM LTD (ASX), BIOHLDG (Bursa), CITIUS PHARMACEUTICALS INC (NASDAQ), AKARI THERAPEUTICS PLC SPON ADR EACH REPR 100 ORD (NASDAQ), PDS BIOTECHNOLOGY CORPORATION (NASDAQ), BAUDAX BIO INC (NASDAQ), MOLECULIN BIOTECH INC (NASDAQ), ALLENA PHARMACEUTICALS INC (NASDAQ), WAI YUEN TONG (HKEx), INVION LTD (ASX), PROPHASE LABS INC (NASDAQ), TBG DIAGNOSTICS LTD (ASX), ADIAL PHARMACEUTICALS INC (NASDAQ), PAINREFORM LTD (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), IMMURON LIMITED (ASX), AILERON THERAPEUTICS INC (NASDAQ), MEDLAB CLINICAL LIMITED (ASX), ACER THERAPEUTICS INC (NASDAQ), SANAI HEALTH GP (HKEx), MANNATECH INC (NASDAQ), ONCTERNAL THERAPEUTICS INC (NASDAQ), EXTRAWELL PHAR (HKEx), PURAPHARM (HKEx), JCT (SET), ANNOVIS BIO INC (NYSE American), DARE BIOSCIENCE INC (NASDAQ), MILLENDO THERAPEUTICS INC (NASDAQ), SUN BIOPHARMA INC (NASDAQ), AGEX THERAPEUTICS INC (NYSE American), CNS PHARMACEUTICALS INC (NASDAQ), EXOPHARM LTD (ASX), HOTH THERAPEUTICS INC (NASDAQ), PHARMAXIS (ASX), SPRING BANK PHARMACEUTICALS INC (NASDAQ), BRICKELL BIOTECH INC (NASDAQ), ACRUX (ASX), ENTERA BIO LTD (NASDAQ), SUNZEN (Bursa), TITAN PHARMACEUTICAL INC (NASDAQ), NOVUS THERAPEUTICS INC (NASDAQ), FIJI KAVA LTD (ASX), SINOLIFE UTD (HKEx), PASHUN INT'L (HKEx), CHINA SXT PHARMACEUTICALS INC (NASDAQ), TALI DIGITAL LIMITED (ASX), TIMBER PHARMACEUTICALS INC (NYSE American), CRESO PHARMA LTD (ASX), SUDA PHARMACEUTICALS LTD (ASX), CELLMID LIMITED (ASX), Merck Sharp Dohme Pharma Tbk. (IDX), FARMAFORCE LTD (ASX), TELIGENT INC NEW (NASDAQ), ORPHAZYME A/S SPON ADS REP 1 ORD SHS (NASDAQ)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days -+0.015
+3.90 %
10 Days -+0.005
+1.27 %
20 Days --0.025
-5.88 %
Medium Term Return 3 Months -+0.105
+35.59 %
6 Months 0.010+0.210
+115.79 %
1 Year 0.010+0.201
+106.03 %
Long Term Return 2 Years 0.016+0.175
+84.89 %
Annualised Return Annualised --
+35.97 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 0.180 - 0.625 Change From 1 Year Low +0.220 % Change From 1 Year Low (%) +122.22
Change From 1 Year High -0.225 % Change From 1 Year High (%) -36.00
2 Years Range 0.160 - 0.625 Change From 2 Years Low +0.240 % Change From 2 Years Low (%) +150.00
Change From 2 Years High -0.225 % Change From 2 Years High (%) -36.00
5 Years Range 0.160 - 0.625 Change From 5 Years Low +0.240 % Change From 5 Years Low (%) +150.00
Change From 5 Years High -0.225 % Change From 5 Years High (%) -36.00
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Hyphens Pharma International Limited and its subsidiaries (the "Group") is one of Singapores leading specialty pharmaceutical and consumer healthcare groups leveraging on its diverse footprint in ASEAN countries. The Group has a direct presence in five ASEAN countries, namely, Singapore, Vietnam, Malaysia, Indonesia and the Philippines, supplemented by a marketing and distribution network covering five additional jurisdictions, namely, Hong Kong, Myanmar, Brunei, Cambodia and Oman. Singapore is the Groups regional headquarters, where its strategic planning, finance, regulatory affairs, research and development, legal, business development and logistics operations are based.The Groups core business comprises the following segments: specialty pharma principals, proprietary brands, and medical hypermart and digital. Besides marketing and selling a range of specialty pharmaceutical products in selected ASEAN countries through exclusive distributorship or licensing and supply agreements with brand principals mainly from Europe and the United States, the Group also develops, markets and sells its own proprietary range of dermatological products and health supplement products. In addition, the Group operates a medical hypermart for healthcare professionals, healthcare institutions and retail pharmacies, to supply pharmaceutical products and medical supplies.

IPO Performance

Listing Date 18 May 2018 Full Subscription Rate (x) 17.91
No of Placement Shares (M) 23.79 No of Public Offer Shares (M) 3.00 Public Offer Subscription Rate (x) 151.99
IPO Price (SGD) a 0.260 First Day Close (SGD) a 0.275 First Week Close (SGD) a 0.260
Current vs IPO Price (%) +53.85 First Day Gain (%) +5.77 First Week Gain (%) -
Notes:
  1. Adjusted for the following: 23,790,000 Placement Shares do not include the 2,810,000 Reserved Shares.

Reports Download

Report Type Financial Year Ended Download
Annual Report
Annual Report 2019 Dec 2019 Part 1(6.40 MB)
Annual Report 2018 Dec 2018 Part 1(7.14 MB)
IPO Prospectus
IPO Prospectus 2018 May 2018 Part 1(2.57 MB)
Part 2(0.27 MB)

Historical Price Data

Date Open High Low Close Volume VWAP
29 Sep 2020 0.420 0.425 0.400 0.405 1,904,000 0.4098
28 Sep 2020 0.425 0.425 0.410 0.420 824,000 0.4162
25 Sep 2020 0.450 0.455 0.420 0.430 1,319,100 0.4331
24 Sep 2020 0.450 0.465 0.435 0.450 5,929,400 0.4520
23 Sep 2020 0.385 0.470 0.385 0.455 13,958,000 0.4322
22 Sep 2020 0.375 0.385 0.370 0.385 808,300 0.3810
21 Sep 2020 0.395 0.395 0.375 0.380 1,415,000 0.3845
18 Sep 2020 0.405 0.410 0.390 0.390 950,900 0.3988
17 Sep 2020 0.395 0.415 0.395 0.400 1,873,800 0.4047
16 Sep 2020 0.395 0.400 0.390 0.395 396,000 0.3949
15 Sep 2020 0.390 0.415 0.390 0.395 2,264,000 0.4029
14 Sep 2020 0.405 0.410 0.385 0.390 1,113,900 0.3941
11 Sep 2020 0.390 0.405 0.390 0.395 1,223,200 0.3968
10 Sep 2020 0.415 0.415 0.380 0.385 2,334,200 0.3931
09 Sep 2020 0.405 0.415 0.405 0.410 1,368,000 0.4089
08 Sep 2020 0.415 0.425 0.410 0.410 2,722,100 0.4158
07 Sep 2020 0.410 0.425 0.405 0.405 751,100 0.4126
04 Sep 2020 0.400 0.415 0.390 0.410 1,076,700 0.4042
03 Sep 2020 0.415 0.450 0.415 0.420 5,840,600 0.4341
02 Sep 2020 0.425 0.425 0.410 0.410 759,500 0.4168
01 Sep 2020 0.410 0.445 0.410 0.425 4,314,400 0.4322
31 Aug 2020 0.420 0.435 0.410 0.415 1,882,400 0.4179
Summary
Current 2 Weeks
(16 Sep 2020 to 29 Sep 2020)
0.395 0.470 0.370 0.405 29,378,500 -
Previous 2 Weeks
(02 Sep 2020 to 15 Sep 2020)
0.425 0.470 0.370 0.395 19,453,300 -
4 Weeks from
(04 Aug 2020 to 01 Sep 2020)
0.605 0.615 0.370 0.425 101,943,100 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.